- $400.42m
- $411.16m
- 16
- 68
- 89
- 59
Annual income statement for Cytodyn, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.266 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | — | -73.3 | -20.6 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 97.1 | 135 | 187 | 45.9 | 38.1 |
| Operating Profit | -97.1 | -135 | -187 | -45.9 | -38.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -124 | -155 | -211 | -79.8 | -49.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -124 | -155 | -211 | -79.8 | -49.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -124 | -155 | -211 | -79.8 | -49.8 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -124 | -155 | -211 | -79.8 | -51.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.242 | -0.194 | -0.251 | -0.089 | -0.032 |